Institutional Research Cancer Epidemiology Fellowship

描述（由申请人提供）：本申请是为约翰霍普金斯彭博公共卫生学院癌症流行病学，预防和控制培训计划的NRSA机构研究资助的5年续期（29-33年）。该计划的使命是培养博士前学生和博士后研究员成为领导者在推进知识的前沿a）癌症的原因，和B）如何通过提供更好地了解癌症相关的行为和识别新的标志物癌症的早期检测来预防它。该计划的目标是为学员创造一个丰富的互动环境，通过公共卫生和医学学院以及Kimmel癌症中心的观察，基础和临床科学家进行的高度创新，富有成效和协作的癌症研究来增强。该计划有3个培训轨道：1）癌症病因学和预防，包括转化研究; 2）癌症遗传流行病学，包括基因组学和表观遗传学;和3）癌症控制，包括差距，沟通和烟草。6个博士前和3个博士后学员追求一个有重点的计划，包括跨轨道的共享元素：关于实质性和方法论主题和研究伦理的教学课程;互动信息交流;教学，沟通，赠款写作经验;博士前或博士后研究;和程序特定的教育，研究和职业指导。强调了开发和测试新假设以及跨学科合作的重要性。通过共享的元素，学员接触到当前的主题，如转化研究，分子流行病学，癌症的新风险因素，癌症研究和筛查的方法学问题，差异，沟通，烟草控制，肥胖，炎症，以及流行病学在风险评估和公共政策中的应用。根据他们的教学、咨询和研究记录选出的19名既定导师负责初级指导。另外34名附属教师为学员提供特定癌症部位，生物统计学和基于实验室的暴露评估方面的尖端专业知识。指导委员会负责受训人员的选择和监测，并随着基于人群的癌症研究的发展完善项目。培训时间通常为4-5年的博士前和2年的博士后学员。该计划具有良好的培训和指导记录：在过去10年中任命的26名博士前和14名博士后学员都有癌症研究培训和职业成功。从大量的申请人中，最好的候选人被招募。学员代表不同的背景;该计划是3个CURE补充的接受者。总之，培训计划旨在a）为学员提供进行最高水平，最先进，协作，转化癌症研究所必需的多学科背景，B）培养他们成为创新思想家，c）发展他们的教学和沟通技能，d）准备他们成为国家癌症研究议程的领导者。

DESCRIPTION (provided by applicant): This application is for the 5-year renewal (Years 29-33) of an NRSA Institutional Research Grant for the training program in Cancer Epidemiology, Prevention, and Control at the Johns Hopkins Bloomberg School of Public Health. The program mission is to train pre-doctoral students and post-doctoral fellows to become leaders at the forefront of advancing the knowledge of a) the causes of cancer, and b) how to prevent it by providing a better understanding of cancer-related behaviors and identifying new markers for the early detection of cancer. The program goal is to create a rich and interactive environment for trainees augmented by the highly innovative, productive, and collaborative cancer research conducted by observational, basic, and clinical scientists at the Schools of Public Health and Medicine and the Kimmel Cancer Center. The program has 3 training tracks: 1) Cancer Etiology and Prevention, including translational research; 2) Genetic Epidemiology of Cancer, including genomics and epigenetics; and 3) Cancer Control, including disparities, communication, and tobacco. The 6 pre- and 3 post-doctoral trainees pursue a focused program consisting of shared elements across the tracks: didactic courses on substantive and methodologic topics and research ethics; interactive information exchange; teaching, communication, grant writing experiences; pre- or post- doctoral research; and program-specific education, research, and career mentoring. The importance of developing and testing novel hypotheses and collaborating across disciplines is stressed. Via the shared elements, the trainees are exposed to current topics, such as translational research, molecular epidemiology, emerging risk factors for cancer, methodologic issues in cancer research and screening, disparities, communication, tobacco control, obesity, inflammation, and use of epidemiology in risk assessment and public policy. Nineteen established preceptors, selected based on their records of teaching, advising, and research, are responsible for primary mentoring. An additional 34 affiliated faculty provide the trainees with cutting-edge expertise in specific cancer sites, biostatistics, and laboratory-based exposure assessment. The steering committee is responsible for trainee selection and monitoring, and program refinement as population-based research on cancer evolves. Training duration is typically 4-5 years for pre- and 2 years for post-doctoral trainees. The program has a strong record of training and mentorship: the 26 pre- and 14 post-doctoral trainees appointed in the past 10 years have cancer research training and career success. From a large pool of applicants, the best possible candidates are recruited. The trainees represent diverse backgrounds; the program is the recipient of 3 CURE supplements. In summary, the training program is designed to a) provide trainees with the multidisciplinary background essential to conduct the highest caliber, state-of-the-art, collaborative, translational cancer research, b) nurture them to be innovative thinkers, c) develop their teaching and communication skills, and d) prepare them to be leaders of the nation's cancer research agenda.